Sofosbuvir;GS-7977;PSI 7977;PSI-7977;GS 7977 NEW

Factory Provide High Quality GS-7977 PSI 7977 CAS 1190307-88-0 Sofosbuvir

Introduction

Product Name : Sofosbuvir

Other name:Isopropyl(2S)-2-{[(S)-{[(2R,3R,4R,5R)-5-(2,4-dioxo-3,4-dihydro-1(2H)-pyrimidinyl)-4-fluoro-3-hydroxy-4-methyChemicalbookltetrahydro-2-furanyl]methoxy}(phenoxy)phosphoryl]amino}propanoate;PSI-7977;GS-7977;PSI7977;GS7977;SOFOSBUVIR

CAS No.:1190307-88-0

MF:C22H29FN3O9P

Purity :99%

MW:529.45

Melting Point :122-124°C

Density :1.41

Appearance: white to off white powder

Storage :Sealed in dry,Sealed in dry,Room Temperature

Sofosbuvir is the world's first oral drug used to treat hepatitis c, one of the most important new drugs approved in the United States in 2013, developed by the American firm gilad science. When it comes to genotype specific hepatitis c, it eliminates the need for traditional injectable drug interferon (IFN).

Sofosbuvir is used to treat chronic hepatitis c virus (HCV) infection. It is the first safe and effective drug to treat HCV infection without IFN. There are several different types of HCV infections. Depending on the type of infection, treatment options can include sofosbuvir and ribavirin, or sofosbuvir, ribavirin and polyethylene glycol interferon alpha.

This product is used for the treatment of genotype 2 and genotype 3 chronic hepatitis C (hepatitis C) adult patients. It can improve the liver function, promote the regeneration of injured liver cells, improve the function of tissue cell respiration and oxygen respiration rate, and reduce the accumulation of fat in the liver.

Application of Sofosbuvir

Sofosbuvir is used raw material of New drugs treating chronic hepatitis C.

1. Sofosbuvir is a kind of hepatitis c virus (HCV) NS5B polymerase inhibitors nucleotide analogues, applicable to as united antiviral treatment composition in the treatment of chronic hepatitis c (CHC) infection.
2. sofosbuvir confirmed by test can effectively treat genotype 1, 2, 3, or 4 c subjects, including within milan criteria are awaiting liver transplantation of HCC subjects and co-infection of HCV/HIV - 1 subjects.